Due to the difficulties in detecting cancer-specific mutations at the early disease stage, we developed a novel approach to specifically enrich mutant KRAS alleles in ctDNA using biotinylated pyrrole–imidazole (PI) polyamides. This evidence concerns the gene KRAS and cancer.